Core Viewpoint - Keda Manufacturing has shown significant stock performance with a year-to-date increase of 72.89%, reflecting strong financial growth and market interest [1][2]. Financial Performance - For the first half of 2025, Keda Manufacturing achieved a revenue of 8.188 billion yuan, representing a year-on-year growth of 49.04% [2]. - The net profit attributable to shareholders for the same period was 745 million yuan, marking a year-on-year increase of 63.95% [2]. Stock Market Activity - As of October 29, Keda Manufacturing's stock price was 13.15 yuan per share, with a market capitalization of 25.22 billion yuan [1]. - The stock experienced a trading volume of 1.06 billion yuan, with a turnover rate of 0.43% [1]. - The stock has seen a net inflow of 872,200 yuan from main funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 19.87% to 59,700, while the average circulating shares per person increased by 24.80% to 32,144 shares [2][3]. - The total cash dividends distributed by Keda Manufacturing since its A-share listing amount to 3.864 billion yuan, with 2.299 billion yuan distributed in the last three years [3]. Business Segments - Keda Manufacturing's main business revenue composition includes overseas building materials (46.06%), building machinery (31.38%), lithium battery materials (11.33%), new energy equipment (8.68%), and others (2.55%) [1].

Core Viewpoint - The stock of Shenzhen Xinlitai Pharmaceutical Co., Ltd. has experienced fluctuations, with a year-to-date increase of 82.91% as of October 29, 2023, despite a recent decline of 2.01% in intraday trading [1][2]. Financial Performance - For the period from January to September 2025, Xinlitai achieved a revenue of 3.241 billion yuan, representing a year-on-year growth of 8.00%, and a net profit attributable to shareholders of 581 million yuan, reflecting a growth of 13.93% [2]. - The company has distributed a total of 7.204 billion yuan in dividends since its A-share listing, with 1.649 billion yuan distributed over the past three years [3]. Stock Market Activity - As of October 29, 2023, Xinlitai's stock price was 55.66 yuan per share, with a market capitalization of 62.051 billion yuan. The trading volume was 48.616 million yuan, with a turnover rate of 0.08% [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on June 17, 2023, where it recorded a net buy of -41.9885 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 25,200, with an average of 44,249 circulating shares per shareholder, a decrease of 4.64% from the previous period [2]. - The top circulating shareholders include China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with significant increases in their holdings [3].

Core Viewpoint - The stock of Shenzhen Sinopharm Co., Ltd. (信立泰) has shown significant growth in 2023, with a year-to-date increase of 88.14%, reflecting strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 3.241 billion yuan, representing a year-on-year growth of 8.00% [2]. - The net profit attributable to shareholders for the same period was 581 million yuan, marking a year-on-year increase of 13.93% [2]. Stock Market Activity - As of October 28, 2023, the stock price reached 57.25 yuan per share, with a trading volume of 2.47 billion yuan and a turnover rate of 0.39% [1]. - The stock has been active on the market, appearing on the "龙虎榜" (top trading list) twice this year, with the most recent instance on June 17, 2023, where it recorded a net buy of -41.9885 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 25,200, up by 4.87% from the previous period [2]. - The top shareholders include 中欧医疗健康混合A (003095) and 香港中央结算有限公司, with significant increases in their holdings [3]. Dividend Distribution - Since its A-share listing, the company has distributed a total of 7.204 billion yuan in dividends, with 1.649 billion yuan distributed over the past three years [3].

Core Points - The stock price of Lianmei Holdings has decreased by 2.11% to 8.83 CNY per share as of October 28, with a total market capitalization of 19.981 billion CNY [1] - The company has experienced a year-to-date stock price increase of 59.59%, with a recent decline of 2.32% over the last five trading days [1] Financial Performance - For the first half of 2025, Lianmei Holdings reported a revenue of 1.898 billion CNY, a year-on-year decrease of 2.65%, while the net profit attributable to shareholders increased by 9.87% to 525 million CNY [2] - The company's main revenue sources include heating and steam income (74.62%), advertising revenue (15.42%), and other services [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 9.21% to 23,400, with an average of 96,587 circulating shares per person, an increase of 10.14% [2] - Lianmei Holdings has distributed a total of 4.044 billion CNY in dividends since its A-share listing, with 1.634 billion CNY distributed in the last three years [3]

Core Viewpoint - Liaoning Chengda's stock price has shown a positive trend with a year-to-date increase of 20.72%, reflecting strong market interest and performance in the pharmaceutical and financial sectors [1][2]. Financial Performance - For the first half of 2025, Liaoning Chengda reported operating revenue of 5.348 billion yuan, a slight decrease of 0.83% year-on-year, while net profit attributable to shareholders increased by 56.18% to 718 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.11 billion yuan, with 411 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 5.14% to 66,000, while the average number of tradable shares per person increased by 5.42% to 23,173 shares [2]. - The top ten circulating shareholders include significant institutional investors, with notable increases in holdings from Southern CSI 500 ETF and Hong Kong Central Clearing Limited [3]. Stock Market Activity - On October 27, the stock price rose by 2.13% to 12.47 yuan per share, with a trading volume of 161 million yuan and a turnover rate of 0.85% [1]. - The net inflow of main funds was 7.2843 million yuan, indicating strong buying interest, particularly from large orders [1].

Core Viewpoint - The stock of Shenzhen Xinlitai Pharmaceutical Co., Ltd. has experienced fluctuations, with a year-to-date increase of 74.53% but a recent decline in the last five trading days by 6.33% [1] Financial Performance - For the first half of 2025, Xinlitai achieved a revenue of 2.131 billion yuan, representing a year-on-year growth of 4.32%, and a net profit attributable to shareholders of 365 million yuan, up by 6.10% [2] - Since its A-share listing, Xinlitai has distributed a total of 7.204 billion yuan in dividends, with 1.649 billion yuan distributed in the last three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders for Xinlitai was 24,000, a decrease of 0.79% from the previous period, with an average of 46,403 circulating shares per person, an increase of 0.80% [2] - The top circulating shareholder is the China Europe Medical Health Mixed Fund A, holding 26.163 million shares, an increase of 12.097 million shares from the previous period [3]

机构持仓方面，截止2025年6月30日，旗滨集团十大流通股东中，景顺长城新能源产业股票A类 （011328）位居第五大流通股东，持股2924.60万股，相比上期减少578.89万股。香港中央结算有限公司 位居第七大流通股东，持股2543.72万股，相比上期增加108.12万股。南方中证500ETF（510500）位居 第八大流通股东，持股2396.37万股，相比上期增加318.77万股。景顺长城成长龙头一年持有期混合A类 （011058）退出十大流通股东之列。 10月23日，旗滨集团盘中下跌2.04%，截至09:48，报6.72元/股，成交4481.05万元，换手率0.25%，总市 值180.34亿元。 资金流向方面，主力资金净流出501.05万元，特大单买入193.69万元，占比4.32%，卖出339.02万元，占 比7.57%；大单买入681.89万元，占比15.22%，卖出1037.61万元，占比23.16%。 旗滨集团今年以来股价涨20.75%，近5个交易日跌5.88%，近20日跌0.88%，近60日涨5.16%。 资料显示，株洲旗滨集团股份有限公司位于广东省深圳市南山区桃源街道龙珠四路2号方大城T1 ...

Core Viewpoint - Shengyi Technology's stock price has shown significant growth this year, with a year-to-date increase of 161.26%, despite a recent decline in the last five trading days [1] Financial Performance - For the first half of 2025, Shengyi Technology reported revenue of 12.68 billion yuan, a year-on-year increase of 31.68%, and a net profit attributable to shareholders of 1.43 billion yuan, up 52.98% year-on-year [2] - Cumulatively, the company has distributed 12.91 billion yuan in dividends since its A-share listing, with 4.55 billion yuan distributed over the last three years [3] Stock Market Activity - As of October 22, Shengyi Technology's stock was trading at 60.22 yuan per share, with a market capitalization of 146.29 billion yuan [1] - The stock has experienced a trading volume of 8.25 billion yuan, with a turnover rate of 0.58% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on March 19, where it recorded a net buy of -548 million yuan [1] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 14.25% to 75,100, while the average circulating shares per person increased by 16.61% to 31,561 shares [2] - Major shareholders include Hong Kong Central Clearing Limited, which holds 166.7 million shares, a decrease of 16.4 million shares from the previous period [3]

机构持仓方面，截止2025年6月30日，科达制造十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1.39亿股，相比上期增加2430.81万股。 责任编辑：小浪快报 科达制造所属申万行业为：机械设备-专用设备-其他专用设备。所属概念板块包括：GDR概念、锂电 池、盐湖提锂、海工装备、分拆概念等。 截至6月30日，科达制造股东户数5.97万，较上期减少19.87%；人均流通股32144股，较上期增加 24.80%。2025年1月-6月，科达制造实现营业收入81.88亿元，同比增长49.04%；归母净利润7.45亿元， 同比增长63.95%。 分红方面，科达制造A股上市后累计派现38.64亿元。近三年，累计派现22.99亿元。 10月20日，科达制造盘中上涨2.02%，截至11:23，报11.64元/股，成交1.05亿元，换手率0.48%，总市值 223.24亿元。 资金流向方面，主力资金净流入391.93万元，特大单买入230.14万元，占比2.20%，卖出0.00元，占比 0.00%；大单买入1493.75万元，占比14.25%，卖出1331.96万元，占比12.70%。 科达制造今年以来股价涨5 ...

Company Overview - Hikvision, established on November 30, 2001, and listed on May 28, 2010, is located in Hangzhou, Zhejiang Province, specializing in the research, production, and sales of security video surveillance products [1] - The company's revenue composition includes 70.00% from main products and services, 7.50% from robotics, 6.58% from smart home, 5.63% from automotive electronics, 4.80% from thermal imaging, 2.47% from storage, 1.87% from construction engineering, and 1.15% from other innovative businesses [1] Financial Performance - For the period from January to September 2025, Hikvision achieved a revenue of 65.758 billion yuan, representing a year-on-year growth of 1.18%, and a net profit attributable to shareholders of 9.319 billion yuan, reflecting a year-on-year increase of 14.94% [2] - Since its A-share listing, Hikvision has distributed a total of 68.502 billion yuan in dividends, with 25.048 billion yuan distributed over the past three years [3] Stock Market Activity - On October 20, Hikvision's stock price decreased by 2.03%, trading at 32.39 yuan per share, with a total transaction volume of 2.408 billion yuan and a turnover rate of 0.80% [1] - The stock has increased by 9.41% year-to-date, with a decline of 2.91% over the last five trading days, a rise of 6.72% over the last 20 days, and an increase of 17.31% over the last 60 days [1] Shareholder Information - As of September 30, 2025, Hikvision had 387,200 shareholders, a decrease of 6.45% from the previous period, with an average of 23,362 circulating shares per shareholder, an increase of 6.10% [2] - Among the top ten circulating shareholders, Huatai-PB CSI 300 ETF holds 63.0512 million shares, having decreased by 2.8907 million shares compared to the previous period [3]